Drug Information Association Logo

INNOVATION IN PRECLINICAL AND CLINICAL SAFETY SCIENCES

Track:
Innovation in R&D Models

Day & Time:
March 27, 11:00AM - 12:30PM (Central European Standard Time)

Session Number:
1406

Room Number:
Room NO

Type:
Session

Title:
INNOVATION IN PRECLINICAL AND CLINICAL SAFETY SCIENCES

Chair(s):
Jonathan Moggs, PhD
Global Head of Molecular Toxicology
Novartis Institutes For Biomedical Research, Switzerland

Description:
The poor prediction of toxicity during early drug development is a major challenge to bringing more effective medicines to patients. Key opportunities for enhancing safety sciences include improved characterisation of molecular, biochemical and cellular pathways of toxicity, together with the development of predictive tools, models and translational safety biomarkers that allow discovery researchers and clinicians to anticipate and mitigate safety issues. A safe harbor approach for amassing preclinical/clinical safety data and exploring chemotype-toxicity relationships is essential for an improved information flow between bedside and bench.

Presentation(s) & Speaker(s):
Safety Assessment of Advanced Therapies
Janis Ancans, PhD
PI; CSO at InCell
University of Latvia, Latvia

Predictability of non-clinical safety models, present and future in debate
Beatriz Silva Lima, PharmD, PhD
Professor
University of Lisboa, Portugal

Novel Insight into Drug Hypersensitivity Mechanisms through Integration of Immunogenetics, Metabolism, Biochemistry and Preclinical Models
Kevin Park
Director of MRC Centre for Drug Safety Science, Head of Institute of Translation
University of Liverpool, United Kingdom